1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Danish Medicine's Agency declines two new reimbursements

 
• By Becky Debens

The Danish Medicines Agencyhas declined two drugs for general reimbursement: Sandoz's anti-inflammatory Migea Rapid (tolfenamic acid), and[C#200001083:Basilea Pharmaceutica]'s eczema treatment Toctino (alitretinoin). Reimbursement decisions are based on Section 144 of the Danish Health Act. The Agency has now reimbursed 19 medicines and declined to reimburse five this year.

The Danish Medicines Agencyhas declined two drugs for general reimbursement: Sandoz's anti-inflammatory Migea Rapid (tolfenamic acid), andBasilea Pharmaceutica's eczema treatment Toctino (alitretinoin). Reimbursement decisions are based on Section 144 of the Danish Health Act. The Agency has now reimbursed 19 medicines and declined to reimburse five this year.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

More from Therapeutic Category

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.